AstraZeneca cancer drug may not be so fast getting to market

LONDON, Nov 5 (Reuters) - AstraZeneca's keenly awaited cancer immunotherapy drug durvalumab may not get to market as quickly as first hoped but the company said on Thursday it was more confident than ever in its oncology development pipeline.